Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients;Polymorphismes du cytochrome P450 2C9 (CYP2C9) et posologie à l'équilibre pour des patients âgés traités par warfarine

Revue de Medecine Interne

Volumn 25, Issue 4, 2004, Pages 271-274

  Siguret, V ^a   Gouin, I ^a   Golmard, J L ^b   Geoffroy, S ^a   Andreux, J P ^a   Pautas, E ^a  

^a HÔPITAL CHARLES FOIX   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

CYP2C9; Cytochrome P450 2C9; Elderly; Sujet g ; Warfarin; Warfarine

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

AGED; AGING; ALLELE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; DOSE RESPONSE; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; THROMBOSIS; WARFARIN;

EID: 1842475297     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.revmed.2003.11.006     Document Type: Article

References (18)

1. Takahashi H., Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 40:2001;587-603.
2. Furuya H., Fernandez-Salguero P., Gregory W., Taber H., Steward A., Gonzalez F.J., et al. Genetic polymorphisms of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics. 7:1995;405-409.
3. Aithal G., Day C., Kesteven P., Daly A. Association of polymorphisms in the cytochrome P450CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 353:1999;717-719.
4. Aithal G., Day C., Kesteven P., Daly A. Association of polymorphisms in the cytochrome P450CYP2C9 with warfarin dose requirement and risk of bleeding complications. Authors' reply. Lancet. 353:1999;1972-1973.
5. Mannucci P.M. Genetic control of anticoagulation. Lancet. 353:1999;688-689.
6. Margaglione M., Colaizzo D., D'Andrea G., Brancaccio V., Ciampa A., Grandone E., et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost. 84:2000;775-778.
7. Taube J., Halsall D., Baglin T. Influence of cytochrome P450CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 96:2000;1816-1819.
8. Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh, Farin F.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 287:2002;1690-1698.
9. Redwood M., Taylor C., Bain B.J., Matthews J.H. The association of age with dosage requirement for warfarin. Age and Ageing. 20:1991;217-220.
10. Gurwitz J.H., Avorn J., Ross-Degnan D., Choodnovsky, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med. 116:1992;901-904.
11. James A.H., Britt R.P., Raskino C.L., Thompson S.G. Factors affecting the maintenance dose of warfarin. J Clin Pathol. 45:1992;704-706.
12. Debray M., Pautas E., Couturier P., Franco A., Siguret V. Anticoagulation orale en pratique gériatrique. Rev Med Interne. 24:2003;107-117.
13. Gentric A., Couturaud F., Mottier D. Anticoagulants chez le sujet âgé. Particularités liées à l'âge. Presse Med. 30:2001;979-982.
14. André E., Siguret V., Alhenc-Gelas M., Saint-Jean O., Gaussem P. Venous thrombosis in older people: prevalence of factor V mutation Q506. J Am Geriatr Soc. 46:1998;1545-1549.
15. Khan T., Kamali F., Daly A., King B., Wynne H.A. Warfarin sensitivity: be aware of genetic influence. Age Ageing. 32:2003;226-227.
16. Wynne H., Cope L., Kelly P., Whittingham T., Edwards C., Kamali F. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol. 40:1995;203-207.
17. Penning-van Beest F.J.A., van Meegen E., Rosendaal F.R., Stricker B.H.C. Characteristics of anticoagulant therapy and comorbidity related overanticoagulation. Thromb Haemost. 86:2001;569-574.
18. Stubbins M.J., Harries M.W., Smith G., Tarbit M.H., Wolf C.R. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 6:1996;429-439.